Centralized Pregnancy Registries May Benefit Small Firms Most - FDA
A centralized pregnancy registry may be most beneficial for smaller pharmaceutical and biotech companies by addressing resource and infrastructure limitations, FDA suggested at a March 29 meeting of the Pregnancy Labeling Subcommittee.
You may also be interested in...
Manufacturers will need to work with FDA to incorporate information on drug experience during pregnancy into product labeling, following publication of an upcoming safety reporting regulation from the agency, Office of Drug Evaluation IV Deputy Director Sandra Kweder, MD, said Dec. 4.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011